Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.62 |
| ▸ | NMUR2 | Q9GZQ4 | 6/20 | 0.58 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | KDM5A | P29375 | 1/20 | 0.57 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.57 |
| ▸ | APLNR | P35414 | 1/20 | 0.57 |
| ▸ | NPY1R | P25929 | 6/20 | 0.56 |
| ▸ | NPY2R | P49146 | 6/20 | 0.56 |
| ▸ | NPY4R | P50391 | 6/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | TFPI | P10646 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957024 | 0.95 | KDM1A (0.61) | KDM1ANPY1RNPY2RNPY4RNPY5R | |
| Neurotensin SCHEMBL30483709 | 0.95 | KDM1A (0.61) | KDM1ANPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30446151 | 0.90 | NMUR2 (0.67) | NMUR2NMUR1APLNRNPY1R | |
| SCHEMBL31302260 | 0.90 | KDM1A (0.58) | KDM1AMAOBKDM5AKDM1BNPY1R | |
| SCHEMBL29356641 | 0.87 | KDM1A (0.65) | KDM1ANMUR2NMUR1MAOBKDM5A | |
| SCHEMBL31307220 | 0.86 | NMUR2 (0.60) | KDM1ANMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL30567748 | 0.86 | NMUR2 (0.65) | KDM1ANMUR2NMUR1NPY1RNPY2R | |
| Neurotensin SCHEMBL29357707 | 0.86 | NTSR1 (0.70) | NMUR2NPY1ROPRM1OPRK1 | |
| Neurotensin SCHEMBL29851748 | 0.86 | NTSR1 (0.70) | NMUR2NPY1ROPRM1OPRK1 | |
| SCHEMBL29930244 | 0.86 | NTSR2 (0.56) | KDM1ANMUR2NMUR1NPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2026-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | SSTR2, SSTR1, SSTR3 | KDM1A 4422/4885NMUR2 230/4885NMUR1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.